BRAF and melanoma: Moreover, we could readily visualize known patterns in the data, such as increased immune module and decreased cell cycle module values in melanomas treated with BRAF inhibitor (“On BRAFi”) in the JCI dataset (Figure 3A), both of which rebounded after drug resistance; and increased cell cycle and decreased skin signatures in recurrent melanomas in the JCOPO dataset, reflecting their known higher mitotic rate and deeper Breslow thickness, respectively.